Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Non-Small-Cell Lung × Tinzaparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thromboembolism 6 Neoplasms 5 Venous Thrombosis 4 Pulmonary Embolism 4 Thromboembolism 2 Lung Neoplasms 2 Thrombosis 1 Thrombocytopenia 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Carboplatin 295 Pemetrexed 240 Cisplatin 203 Docetaxel 170 Paclitaxel 158 Radiotherapy 156 Erlotinib Hydrochloride 143 pembrolizumab 134 Gemcitabine 124 Bevacizumab 115 Drug Therapy 100 Radiosurgery 95 Nivolumab 95 durvalumab 79 osimertinib 77 Gefitinib 59 atezolizumab 57 Surgical Procedures, Operative 55 Vinorelbine 54 Magnetic Resonance Spectroscopy 52 Taxes 37 Immunotherapy 37 130-nm albumin-bound paclitaxel 35 anlotinib 34 Specimen Handling 34 Ipilimumab 33 Blood Specimen Collection 33 Immune Checkpoint Inhibitors 31 Albumin-Bound Paclitaxel 31 Radiation 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00475098 2016-09-02

TILT

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡